Tapentadol (Palexia®)

Assessment Status Assessment process complete
Drug Tapentadol
Brand Palexia®
Indication For the management of adult patients with severe chronic/acute pain.
Assessment Process
Rapid review commissioned 19/10/2010
Rapid review completed 22/10/2020
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 31/01/2011
NCPE assessment completed 08/04/2011
NCPE assessment outcome Reimbursement Recommended

Tapentadol (Palexia®) may be considered cost-effective but should be reserved for patients who cannot tolerate existing strong oral opioids.

Technical Summary